Clarify the Role of Opzelura for Eczema

Opzelura (ruxolitinib) 1.5% cream will be the first topical Janus kinase (JAK) inhibitor approved for mild to moderate eczema.

It suppresses cytokines to improve itching and inflammation.

Opzelura is thought to be safer than oral JAK inhibitors (Xeljanz, etc)...since it seems to have less than 10% systemic absorption.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote